Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma

High-grade glioma (HGG) and glioblastoma are the most common adult malignant brain tumors. The standard treatment consists of surgical resection followed by radiochemotherapy with temozolomide. The prognosis and the therapeutic options of these malignant brain tumors however are limited. Here, we de...

Descripción completa

Detalles Bibliográficos
Autores principales: König, David, Hench, Jürgen, Frank, Stephan, Dima, Laura, Bratic Hench, Ivana, Läubli, Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254302/
https://www.ncbi.nlm.nih.gov/pubmed/35526519
http://dx.doi.org/10.1159/000524399
Descripción
Sumario:High-grade glioma (HGG) and glioblastoma are the most common adult malignant brain tumors. The standard treatment consists of surgical resection followed by radiochemotherapy with temozolomide. The prognosis and the therapeutic options of these malignant brain tumors however are limited. Here, we describe a case of a patient with HGG with a previously unknown NTRK3 fusion that showed an extraordinary response to treatment with larotrectinib. This case supports regular testing for NTRK fusion proteins.

Ejemplares similares